Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysis.
Eldani C, Kostine M, Faure M, Lazaro E, Rigothier C, Hiriart JB, Teulières B, Poullenot F, Haissaguerre M, Zysman M, Veillon R, Vergnenegre C, Issa N, Domblides C, Mary-Prey S, Beylot-Barry M, Pham-Ledard A, Dutriaux C, Sole G, Duval F, Gerard E.
Eldani C, et al. Among authors: duval f.
Front Oncol. 2024 Jul 8;14:1403658. doi: 10.3389/fonc.2024.1403658. eCollection 2024.
Front Oncol. 2024.
PMID: 39040444
Free PMC article.